291 related articles for article (PubMed ID: 8571320)
1. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor.
Lindhout T; Franssen J; Willems G
Thromb Haemost; 1995 Sep; 74(3):910-5. PubMed ID: 8571320
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of factor X activation at extracellular matrix of fibroblasts during flow conditions: a comparison between tissue factor pathway inhibitor and inactive factor VIIa.
Valentin S; Reutlingsperger CP; Nordfang O; Lindhout T
Thromb Haemost; 1995 Dec; 74(6):1478-85. PubMed ID: 8772224
[TBL] [Abstract][Full Text] [Related]
3. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
Iakhiaev A; Ruf W; Rao LV
Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
[TBL] [Abstract][Full Text] [Related]
4. The importance of the binding of factor Xa to phospholipids in the inhibitory mechanism of tissue factor pathway inhibitor: the transmembrane and cytoplasmic domains of tissue factor are not essential for the inhibitory action of tissue factor pathway inhibitor.
Kazama Y
Thromb Haemost; 1997 Mar; 77(3):492-7. PubMed ID: 9066000
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin.
Jesty J; Wun TC; Lorenz A
Biochemistry; 1994 Oct; 33(42):12686-94. PubMed ID: 7918495
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
Lefkovits J; Malycky JL; Rao JS; Hart CE; Plow EF; Topol EJ; Nicolini FA
J Am Coll Cardiol; 1996 Dec; 28(7):1858-65. PubMed ID: 8962577
[TBL] [Abstract][Full Text] [Related]
7. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
8. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
Rao LV; Ruf W
Biochemistry; 1995 Aug; 34(34):10867-71. PubMed ID: 7662667
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
[TBL] [Abstract][Full Text] [Related]
10. Structure of extracellular tissue factor complexed with factor VIIa inhibited with a BPTI mutant.
Zhang E; St Charles R; Tulinsky A
J Mol Biol; 1999 Feb; 285(5):2089-104. PubMed ID: 9925787
[TBL] [Abstract][Full Text] [Related]
11. Phospholipid regulates the activation of factor X by tissue factor/factor VIIa (TF/VIIa) via substrate and product interactions.
Hathcock JJ; Rusinova E; Gentry RD; Andree H; Nemerson Y
Biochemistry; 2005 Jun; 44(22):8187-97. PubMed ID: 15924438
[TBL] [Abstract][Full Text] [Related]
12. The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.
Burgering MJ; Orbons LP; van der Doelen A; Mulders J; Theunissen HJ; Grootenhuis PD; Bode W; Huber R; Stubbs MT
J Mol Biol; 1997 Jun; 269(3):395-407. PubMed ID: 9199408
[TBL] [Abstract][Full Text] [Related]
13. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H
Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186
[TBL] [Abstract][Full Text] [Related]
14. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.
Hackeng TM; Seré KM; Tans G; Rosing J
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3106-11. PubMed ID: 16488980
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant actions of tissue factor pathway inhibitor on tissue-factor-dependent plasma coagulation.
Ofosu FA
Semin Thromb Hemost; 1995; 21(2):240-4. PubMed ID: 7660146
[TBL] [Abstract][Full Text] [Related]
16. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.
Salemink I; Franssen J; Willems GM; Hemker HC; Li A; Wun TC; Lindhout T
Thromb Haemost; 1998 Aug; 80(2):273-80. PubMed ID: 9716152
[TBL] [Abstract][Full Text] [Related]
17. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
[TBL] [Abstract][Full Text] [Related]
18. The lipoprotein-associated coagulation inhibitor.
Broze GJ; Girard TJ; Novotny WF
Prog Hemost Thromb; 1991; 10():243-68. PubMed ID: 2008533
[TBL] [Abstract][Full Text] [Related]
19. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat.
Han X; Girard TJ; Baum P; Abendschein DR; Broze GJ
Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2563-7. PubMed ID: 10521388
[TBL] [Abstract][Full Text] [Related]
20. The effect of leukocyte elastase on tissue factor pathway inhibitor.
Higuchi DA; Wun TC; Likert KM; Broze GJ
Blood; 1992 Apr; 79(7):1712-9. PubMed ID: 1558967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
